[HTML][HTML] Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance …
Background Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and
14 weeks of age was introduced in Kenya in January, 2011, accompanied by a catch-up …
14 weeks of age was introduced in Kenya in January, 2011, accompanied by a catch-up …
Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults
A Thompson, E Lamberth, J Severs, I Scully, S Tarabar… - Vaccine, 2019 - Elsevier
Introduction Streptococcus pneumoniae is a leading cause of bacteremia, bacterial
pneumonia, and meningitis, and is associated with substantial morbidity and mortality …
pneumonia, and meningitis, and is associated with substantial morbidity and mortality …
Preliminary report from the World Health Organisation chest radiography in epidemiological studies project
Childhood pneumonia is among the leading infectious causes of mortality in children
younger than 5 years of age globally. Streptococcus pneumoniae (pneumococcus) is the …
younger than 5 years of age globally. Streptococcus pneumoniae (pneumococcus) is the …
SeroBA: rapid high-throughput seroty** of Streptococcus pneumoniae from whole genome sequence data
Streptococcus pneumoniae is responsible for 240 000–460 000 deaths in children under 5
years of age each year. Accurate identification of pneumococcal serotypes is important for …
years of age each year. Accurate identification of pneumococcal serotypes is important for …
Estimated severe pneumococcal disease cases and deaths before and after pneumococcal conjugate vaccine introduction in children younger than 5 years of age in …
C Von Mollendorf, S Tempia, A Von Gottberg… - PloS one, 2017 - journals.plos.org
Introduction Streptococcus pneumoniae is a leading cause of severe bacterial infections
globally. A full understanding of the impact of pneumococcal conjugate vaccine (PCV) on …
globally. A full understanding of the impact of pneumococcal conjugate vaccine (PCV) on …
[HTML][HTML] Pneumococcal conjugate vaccines and hospitalization of children for pneumonia: a time-series analysis, South Africa, 2006–2014
A Izu, F Solomon, SA Nzenze, A Mudau… - Bulletin of the World …, 2017 - ncbi.nlm.nih.gov
Objective To assess the impact of immunization with pneumococcal conjugate vaccines on
all-cause pneumonia hospitalizations among children in Soweto, South Africa. Methods We …
all-cause pneumonia hospitalizations among children in Soweto, South Africa. Methods We …
Streptococcus pneumoniae Causing Invasive Diseases in Children and Adults in Central Thailand, 2012–2016
W Phongsamart, S Srifeungfung, T Chatsuwan… - Vaccines, 2022 - mdpi.com
Longitudinal data regarding the serotype distribution and antimicrobial susceptibility of S.
pneumoniae-causing invasive pneumococcal disease (IPD) in develo** countries are …
pneumoniae-causing invasive pneumococcal disease (IPD) in develo** countries are …
When less is more: how many doses of PCV are enough?
KL O'Brien - The Lancet Infectious Diseases, 2018 - thelancet.com
Pneumococcal conjugate vaccine (PCV) is an incredibly important, lifesaving vaccine, first
licensed in 2000, 1 and recommended for infant routine use in the UK in 2006. 2 Since 2007 …
licensed in 2000, 1 and recommended for infant routine use in the UK in 2006. 2 Since 2007 …
Pneumococcal serotypes in children, clinical presentation and antimicrobial susceptibility in the PCV13 era
C Izquierdo, P Ciruela, S Hernández… - Epidemiology & …, 2020 - cambridge.org
The aim was to analyse invasive pneumococcal disease (IPD) serotypes in children aged⩽
17 years according to clinical presentation and antimicrobial susceptibility. We conducted a …
17 years according to clinical presentation and antimicrobial susceptibility. We conducted a …
Global distribution of invasive serotype 35D Streptococcus pneumoniae isolates following introduction of 13-valent pneumococcal conjugate vaccine
ABSTRACT A newly recognized pneumococcal serotype, 35D, which differs from the 35B
polysaccharide in structure and serology by not binding to factor serum 35a, was recently …
polysaccharide in structure and serology by not binding to factor serum 35a, was recently …